Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
Outcomes in COVID-19 molnupiravir studies
Outcomes in molnupiravir studies. Potential risks of the mechanism of action include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity [Hadj Hassine, Swanstrom, Waters]. See [Fountain-Jones, Sanderson, twitter.com] for analysis of variants potentially created by molnupiravir. There is substantial publication bias. Two trials (CTRI/2021/05/033864 and CTRI/2021/08/0354242) reported no significant efficacy, however the results have not been published. Multiple trials have not reported results and did not respond to requests [Lawrence].
0 0.5 1 1.5+ All studies 16% 30 104,953 Improvement, Studies, Patients Relative Risk Mortality 23% 15 83,307 Ventilation 46% 5 7,016 ICU admission 19% 3 1,836 Hospitalization 2% 18 79,431 Progression 25% 5 33,432 Recovery 19% 7 25,629 Viral clearance 32% 9 7,043 RCTs 41% 12 30,687 RCT mortality 45% 4 26,955 Peer-reviewed 22% 21 76,802 Early 18% 26 81,226 Late 11% 4 23,727 Molnupiravir for COVID-19 c19early.org/m Mar 2023 Favorsmolnupiravir Favorscontrol after exclusions
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] death 4/845 137/12,724 Arbel 40-64 -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] death 3/12,529 5/12,525 Wong (PSM) 24% 0.76 [0.61-0.95] death Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT​1 Bajema (PSM) 18% 0.82 [0.52-1.29] death 24/897 29.0/897 Inaba 58% 0.42 [0.02-10.1] death 0/84 1/210 Zheng (PSW) -285% 3.85 [1.54-10.0] death/hosp. 11/802 33/4,836 OT​1 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Tau​2 = 0.31, I​2 = 80.9%, p = 0.17 Early treatment 18% 0.82 [0.61-1.09] 239/26,688 538.0/54,538 18% improvement 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​2 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​2 Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Tau​2 = 0.00, I​2 = 0.0%, p = 0.0047 Late treatment 11% 0.89 [0.83-0.97] 715/6,369 2,542/17,358 11% improvement All studies 16% 0.84 [0.67-1.05] 954/33,057 3,080.0/71,896 16% improvement 30 molnupiravir COVID-19 studies c19early.org/m Mar 2023 Tau​2 = 0.19, I​2 = 80.3%, p = 0.12 Effect extraction pre-specified 1 OT: comparison with other treatment2 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] death 4/845 137/12,724 Arbel 40-64 -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] death 3/12,529 5/12,525 Wong (PSM) 24% 0.76 [0.61-0.95] death Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT​1 Bajema (PSM) 18% 0.82 [0.52-1.29] death 24/897 29.0/897 Inaba 58% 0.42 [0.02-10.1] death 0/84 1/210 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Tau​2 = 0.25, I​2 = 77.9%, p = 0.026 Early treatment 27% 0.73 [0.56-0.96] 220/25,444 503.0/49,480 27% improvement 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​2 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​2 Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Tau​2 = 0.00, I​2 = 0.0%, p = 0.0047 Late treatment 11% 0.89 [0.83-0.97] 715/6,369 2,542/17,358 11% improvement All studies 23% 0.77 [0.62-0.96] 935/31,813 3,045.0/66,838 23% improvement 28 molnupiravir COVID-19 studies after exclusions c19early.org/m Mar 2023 Tau​2 = 0.16, I​2 = 78.5%, p = 0.018 Effect extraction pre-specified 1 OT: comparison with other treatment2 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] 1/709 9/699 Wong (PSM) 52% 0.48 [0.40-0.59] 1,856 (n) 1,856 (n) Flisiak 39% 0.61 [0.38-0.97] 20/203 63/387 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] 22/2,661 27/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] 4/845 137/12,724 Arbel 40-64 -1182% 12.82 [3.41-48.2] 4/224 7/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] 2/230 3/690 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] 3/12,529 5/12,525 Wong (PSM) 24% 0.76 [0.61-0.95] Bajema (PSM) 18% 0.82 [0.52-1.29] 24/897 29.0/897 Inaba 58% 0.42 [0.02-10.1] 0/84 1/210 Goodwin -110% 2.10 [0.19-22.9] 1/80 2/336 Tau​2 = 0.20, I​2 = 72.9%, p = 0.094 Early treatment 27% 0.73 [0.51-1.06] 81/20,458 284.0/39,122 27% improvement Arribas (DB RCT) -282% 3.82 [0.50-29.1] 11/216 1/75 Improvement, RR [CI] Treatment Control Wan 11% 0.89 [0.81-0.98] 704/6,153 2,541/17,283 Tau​2 = 0.52, I​2 = 49.4%, p = 0.71 Late treatment -28% 1.28 [0.37-4.38] 715/6,369 2,542/17,358 28% increased risk All studies 23% 0.77 [0.57-1.03] 796/26,827 2,826.0/56,480 23% improvement 15 molnupiravir COVID-19 mortality results c19early.org/m Mar 2023 Tau​2 = 0.14, I​2 = 79.5%, p = 0.08 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wong (PSM) 58% 0.42 [0.17-1.01] 1,856 (n) 1,856 (n) Improvement, RR [CI] Treatment Control Flisiak 5% 0.95 [0.39-2.32] 7/203 14/387 Suzuki (PSM) 57% 0.43 [0.02-10.5] 0/230 1/690 Wong (PSM) 60% 0.40 [0.19-0.84] Bajema (PSM) 17% 0.83 [0.17-4.12] 3/897 3.6/897 Tau​2 = 0.00, I​2 = 0.0%, p = 0.0083 Early treatment 46% 0.54 [0.34-0.85] 10/3,186 18.6/3,830 46% improvement All studies 46% 0.54 [0.34-0.85] 10/3,186 18.6/3,830 46% improvement 5 molnupiravir COVID-19 mechanical ventilation results c19early.org/m Mar 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.0083 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wong (PSM) 26% 0.74 [0.45-1.21] Improvement, RR [CI] Treatment Control Liu -162% 2.62 [0.11-60.6] 1/26 0/16 Bajema (PSM) 1% 0.99 [0.41-2.37] 10/897 10.1/897 Tau​2 = 0.00, I​2 = 0.0%, p = 0.35 Early treatment 19% 0.81 [0.53-1.25] 11/923 10.1/913 19% improvement All studies 19% 0.81 [0.53-1.25] 11/923 10.1/913 19% improvement 3 molnupiravir COVID-19 ICU results c19early.org/m Mar 2023 Tau​2 = 0.00, I​2 = 0.0%, p = 0.35 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 6% 0.94 [0.89-1.00] hosp. time 1,856 (n) 1,856 (n) Yip (PSW) -17% 1.17 [0.99-1.39] hosp. Flisiak -1% 1.01 [0.71-1.43] hosp. time 203 (n) 387 (n) AGILE CST-2 Khoo (DB RCT) 89% 0.11 [0.01-2.03] hosp. 0/90 4/90 Arbel 65+ 45% 0.55 [0.34-0.88] hosp. 18/845 513/12,724 Arbel 40-64 -80% 1.80 [0.86-3.77] hosp. 8/224 97/6,075 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) -7% 1.07 [0.81-1.41] hosp. 103/12,529 96/12,525 Wong (PSM) 2% 0.98 [0.89-1.06] hosp. Liu 18% 0.82 [0.63-1.06] hosp. time 26 (n) 16 (n) Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Bajema (PSM) -30% 1.30 [1.01-1.68] hosp. 162/897 124.3/897 Inaba -127% 2.27 [0.60-7.25] hosp. 5/84 8/210 Goodwin 58% 0.42 [0.05-3.23] hosp. 1/80 10/336 Tau​2 = 0.02, I​2 = 69.9%, p = 0.6 Early treatment 3% 0.97 [0.86-1.09] 331/19,005 917.3/36,990 3% improvement Wan 1% 0.99 [0.93-1.05] hosp. 2,298/6,153 2,541/17,283 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.7 Late treatment 1% 0.99 [0.93-1.05] 2,298/6,153 2,541/17,283 1% improvement All studies 2% 0.98 [0.90-1.08] 2,629/25,158 3,458.3/54,273 2% improvement 18 molnupiravir COVID-19 hospitalization results c19early.org/m Mar 2023 Tau​2 = 0.01, I​2 = 68.1%, p = 0.73 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Arbel 65+ 74% 0.26 [0.10-0.73] death 4/845 137/12,724 Arbel 40-64 -1182% 12.82 [3.41-48.2] death 4/224 7/6,075 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] death 3/12,529 5/12,525 Wong (PSM) 24% 0.76 [0.61-0.95] death Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT​1 Bajema (PSM) 18% 0.82 [0.52-1.29] death 24/897 29.0/897 Inaba 58% 0.42 [0.02-10.1] death 0/84 1/210 Zheng (PSW) -285% 3.85 [1.54-10.0] death/hosp. 11/802 33/4,836 OT​1 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Tau​2 = 0.32, I​2 = 80.4%, p = 0.26 Early treatment 16% 0.84 [0.62-1.14] 193/26,501 442.0/54,352 16% improvement Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Improvement, RR [CI] Treatment Control Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Tau​2 = 0.52, I​2 = 49.4%, p = 0.71 Late treatment -28% 1.28 [0.37-4.38] 715/6,369 2,542/17,358 28% increased risk All studies 15% 0.85 [0.67-1.08] 908/32,870 2,984.0/71,710 15% improvement 26 molnupiravir COVID-19 serious outcomes c19early.org/m Mar 2023 Tau​2 = 0.19, I​2 = 80.4%, p = 0.19 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hetero (RCT) 33% 0.67 [0.54-0.82] recov. time 371 (n) 370 (n) Improvement, RR [CI] Treatment Control Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 AGILE CST-2 Khoo (DB RCT) -12% 1.12 [0.71-1.79] no recov. 27/90 24/90 PANORAMIC Butler (RCT) 22% 0.78 [0.75-0.81] no recov. 3,856/12,403 4,838/12,140 Tau​2 = 0.01, I​2 = 50.4%, p = 0.0059 Early treatment 21% 0.79 [0.66-0.93] 3,891/12,876 4,865/12,606 21% improvement 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Arribas (DB RCT) 1% 0.99 [0.68-1.45] no recov. 72 (n) 75 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.97 Late treatment 1% 0.99 [0.74-1.34] 0/72 0/75 1% improvement All studies 19% 0.81 [0.71-0.92] 3,891/12,948 4,865/12,681 19% improvement 7 molnupiravir COVID-19 recovery results c19early.org/m Mar 2023 Tau​2 = 0.01, I​2 = 30.0%, p = 0.0017 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Improvement, RR [CI] Treatment Control Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Tippabhotla (RCT) 59% 0.41 [0.29-0.57] viral+ 42/610 103/610 Wong (PSM) 28% 0.72 [0.61-0.87] viral+ 1,856 (n) 1,856 (n) AGILE CST-2 Khoo (DB RCT) 23% 0.77 [0.58-1.09] viral+ 90 (n) 90 (n) PANORAMIC Butler (RCT) -95% 1.95 [1.15-3.31] viral load 21 (n) 11 (n) Liu 21% 0.79 [0.59-1.05] viral time 26 (n) 16 (n) Sinha (RCT) 48% 0.52 [0.42-0.63] viral load 608 (n) 610 (n) Tau​2 = 0.10, I​2 = 82.8%, p = 0.0012 Early treatment 35% 0.65 [0.51-0.84] 90/3,504 205/3,427 35% improvement Arribas (DB RCT) 12% 0.88 [0.62-1.25] viral+ 26/52 34/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.49 Late treatment 12% 0.88 [0.62-1.25] 26/52 34/60 12% improvement All studies 32% 0.68 [0.53-0.86] 116/3,556 239/3,487 32% improvement 9 molnupiravir COVID-19 viral clearance results c19early.org/m Mar 2023 Tau​2 = 0.10, I​2 = 81.8%, p = 0.0013 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] death 3/12,529 5/12,525 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Tau​2 = 0.04, I​2 = 15.0%, p < 0.0001 Early treatment 55% 0.45 [0.32-0.62] 73/15,244 174/15,152 55% improvement 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Tau​2 = 0.00, I​2 = 0.0%, p = 0.77 Late treatment -8% 1.08 [0.67-1.73] 11/216 1/75 8% increased risk All studies 41% 0.59 [0.40-0.86] 84/15,460 175/15,227 41% improvement 12 molnupiravir COVID-19 Randomized Controlled Trials c19early.org/m Mar 2023 Tau​2 = 0.18, I​2 = 49.5%, p = 0.0069 Effect extraction pre-specified 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] 1/709 9/699 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] 3/12,529 5/12,525 Tau​2 = 0.00, I​2 = 0.0%, p = 0.048 Early treatment 67% 0.33 [0.11-0.99] 4/13,378 15/13,286 67% improvement Arribas (DB RCT) -282% 3.82 [0.50-29.1] 11/216 1/75 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Late treatment -282% 3.82 [0.50-29.1] 11/216 1/75 282% increased risk All studies 45% 0.55 [0.13-2.38] 15/13,594 16/13,361 45% improvement 4 molnupiravir COVID-19 RCT mortality results c19early.org/m Mar 2023 Tau​2 = 1.13, I​2 = 51.1%, p = 0.43 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Improvement, RR [CI] Treatment Control Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Wong (PSM) 52% 0.48 [0.40-0.59] death 1,856 (n) 1,856 (n) Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Flisiak 39% 0.61 [0.38-0.97] death 20/203 63/387 AGILE CST-2 Khoo (DB RCT) 67% 0.33 [0.01-8.08] oxygen 0/90 1/90 Kneidinger -15% 1.15 [0.56-2.37] severe case 8/46 26/172 Najjar-Deb.. (PSM) 19% 0.81 [0.46-1.43] death 22/2,661 27/2,661 Suzuki (PSM) -100% 2.00 [0.34-11.9] death 2/230 3/690 Brown -101% 2.01 [0.43-9.38] hosp. 8/442 2/222 PANORAMIC Butler (RCT) 40% 0.60 [0.14-2.51] death 3/12,529 5/12,525 Wong (PSM) 24% 0.76 [0.61-0.95] death Liu -162% 2.62 [0.11-60.6] ICU 1/26 0/16 Sinha (RCT) 65% 0.35 [0.16-0.73] hosp. 9/608 26/610 Zheng -100% 2.00 [1.23-3.23] death/hosp. 61/2,689 34/3,331 OT​1 Evans 51% 0.49 [0.29-0.83] death/hosp. 359 (n) 4,973 (n) Goodwin -110% 2.10 [0.19-22.9] death 1/80 2/336 Tau​2 = 0.20, I​2 = 74.2%, p = 0.045 Early treatment 25% 0.75 [0.57-0.99] 158/23,521 237/29,554 25% improvement Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Improvement, RR [CI] Treatment Control Wan 11% 0.89 [0.81-0.98] death 704/6,153 2,541/17,283 Tau​2 = 0.52, I​2 = 49.4%, p = 0.71 Late treatment -28% 1.28 [0.37-4.38] 715/6,369 2,542/17,358 28% increased risk All studies 22% 0.78 [0.62-0.98] 873/29,890 2,779/46,912 22% improvement 21 molnupiravir COVID-19 peer reviewed studies c19early.org/m Mar 2023 Tau​2 = 0.12, I​2 = 76.1%, p = 0.03 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors molnupiravir Favors control